We reach more than 65,000 registered users in Dec!! Register Now
EMA to quickly review Eli Lilly, Incyte arthritis drug for COVID-19 use
- May 03, 2021
- 49 Views
- 0 Likes
- 0 Comment
The European Medicines Agency will conduct an accelerated review of Eli Lilly and Co's rheumatoid arthritis drug Olumiant for hospitalized COVID-19 patients getting oxygen, the agency said on Thursday, as the search for treatment options continues.
Cite This Article as
"EMA to quickly review Eli Lilly, Incyte arthritis drug for COVID-19 use", MachPrinciple, May 03, 2021, https://machprinciple.com/post/EMA-to-quickly-review-Eli-Lilly-Incyte-arthritis-drug-for-COVID-19-use
